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E-mail: aconway@sangamo.comThere is a strong rationale to consider future cell therapeutic
approaches for cystic fibrosis (CF) in which autologous prox-
imal airway basal stem cells, corrected for CFTR mutations,
are transplanted into the patient’s lungs. We assessed the pos-
sibility of editing the CFTR locus in these cells using zinc-finger
nucleases and have pursued two approaches. The first, muta-
tion-specific correction, is a footprint-free method replacing
the CFTRmutation with corrected sequences. We have applied
this approach for correction of DF508, demonstrating restora-
tion of mature CFTR protein and function in air-liquid inter-
face cultures established from bulk edited basal cells. The sec-
ond is targeting integration of a partial CFTR cDNA within
an intron of the endogenous CFTR gene, providing correction
for all CFTR mutations downstream of the integration and ex-
ploiting the native CFTR promoter and chromatin architecture
for physiologically relevant expression. Without selection, we
observed highly efficient, site-specific targeted integration in
basal cells carrying various CFTRmutations and demonstrated
restored CFTR function at therapeutically relevant levels.
Significantly, Omni-ATAC-seq analysis revealed minimal
impact on the positions of open chromatin within the native
CFTR locus. These results demonstrate efficient functional
correction of CFTR and provide a platform for further
ex vivo and in vivo editing.
INTRODUCTION
There is still much to be learned about turnover of cells in the human
airway, as well as the identity of potential stem/progenitor cells
responsible for overall pulmonary architecture and maintenance.
There is an emerging consensus, however, that pseudo-stratified
epithelial tissue of the human proximal airway contains basal cells
capable both of self-renewing cell division, as well as differentiation
to other specialized cells, including ciliated and secretory cells. As
such, proximal airway basal cells serve as a major class of stem/pro-
genitor cells within the proximal airway.1–4 Thus, there is strong
rationale to consider future cell therapeutic approaches for CF inwhich autologous proximal airway basal cells, corrected for CFTR
gene mutations, are transplanted into the lungs of affected CF pa-
tients. To that end, our objective has been to prepare a population
of CFTR corrected, patient-specific airway basal cells, which retain
the ability to develop pseudo-stratified airway epithelium with
restored CFTR function. Several groups, including our own, have uti-
lized various methods to directly correct or compensate for CFTR
mutations in relevant cell types via editing or gene transfer.5–21
There is currently uncertainty about the relative contribution of
different cell types to overall CFTR activity in the airway epithelium.
Does the rare ionocyte population expressing high levels of CFTR
dominate22,23 or do other more abundant luminal cell types (secretory
or ciliated), which apparently express CFTR at lower levels per cell,
also contribute?24 Importantly, the aforementioned cell types are
derived from airway basal stem cells, which justifies our editing
focus.2,3,22
It is important to consider frequencies at which cells in the CF
airway would need to be corrected, either as a consequence of
transplantation of edited airway basal cells or direct in vivo editing,
for therapeutic benefit. Johnson et al.25 reported that as few as 6%–
10% corrected cells was sufficient to restore CF chloride ion trans-
port levels to normal. A second study showed that 5% of pseudos-
tratified epithelial cells expressing CFTR corrected the CF chloride
transport defect.26 However, these two studies used highly efficient
viral vector promoters to express CFTR and therefore it cannot be
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Figure 1. Site-Specific Editing of CF Airway Basal
Cells
(A) Site-specific correction of DF508 mediated by tar-
geted nuclease cleavage with wild-type DNA template
serving as donor. (B) Integration of CFTR9-27 cDNA (en-
coding exons 9–27), preceded by a splice acceptor (SA),
followed by polyadenylation (pA) sequences, and flanked
by homology sequences, into CFTR intron 8; the spliced
mRNA joins endogenous exon 8 with the exon 9–27
transgene.assured that comparable results would be obtained in differentiated
human airway epithelia where CFTR is under the control of its
endogenous promoter. In mixing experiments of human airway
cells in air-liquid interface (ALI) cultures, it was reported that
20% of non-CF cells mixed into a background of 80% DF508/
DF508 cells yielded CFTR chloride current at levels 70% of wild-
type levels.27 These data supported the concept that even a small
fraction of cells expressing CFTR from the endogenous CFTR locus
would be sufficient to correct the chloride transport defect in CF
cells.27
The two approaches for CFTR gene editing in CF airway basal cells
pursued by this study are shown in Figure 1. Our rationale for per-
forming gene editing specifically of the endogenous CFTR locus re-
flects an intent to achieve expression of the corrected CFTR gene at
close to physiologic levels. The first approach is site-specific correc-
tion of CFTR mutations; namely, a footprint-free method replacing
mutant CFTR sequences with the corrected sequences (Figure 1A).
Because CF is a recessive disease, correction of only one CFTR allele
per cell would be sufficient for rescue of CFTR function. Site-specific
correction of CFTR mutations in the endogenous gene is expected to
result in physiologically appropriate levels of CFTR protein and func-
tion. However, site-specific correction typically requires a distinct set
of sequence-directed nuclease and oligonucleotide donor reagents for
each CFTRmutation. Because approximately 2,000 different CF-asso-
ciated mutations have been reported, the sequence-specific approach
would only seem justified for the most frequently occurring variants
such as DF508. The second approach is homologous recombination-
mediated targeted integration (TI) of a codon optimized partial CFTR
cDNA (also denoted as a “super-exon”)5,7 preceded by a splice
acceptor (SA) and followed by a polyadenylation (pA) sequence,
within an intron of the endogenous CFTR gene (Figure 1B). This
approach is capable of providing correction for all CFTR mutations
downstream of the targeted partial CFTR cDNA integration site.
Furthermore, by targeting cleavage of the genomic DNA within in-
tronic versus exonic sequences, the possibility that nuclease-inducedindels will adversely impact uncorrected alleles
is minimized. With the objective of achieving
physiologically regulated levels of CFTR expres-
sion and function, this approach would also
benefit, in principle, from endogenous CFTR
promoter activity and native chromatin archi-tecture, provided that TI of the partial CFTR cDNA does not disrupt
chromatin architecture in edited cells.
RESULTS
Feeder-free Expansion of Primary Airway Basal Cells with
Retention of CFTR Function
Starting with early passage primary human airway epithelial cells
from explanted CF or non-CF lungs, we first compared feeder-free
culture methodologies for their ability to expand airway basal cells
for numerous passages while retaining functional capability. Both
the previously reported dual SMAD inhibition medium28 and Pneu-
macult Ex-Plus medium allowed for continuous proliferation to at
least passage 12 (p12; corresponding to 35–37 population doublings
[PDs]; Figure S1A) while retaining markers characteristic of basal
cells (e.g., CD49f, NGFR; Figure S1B). In order to assay functionality,
expanded cells at various passage numbers were plated onto porous
membranes and subject to ALI culture to assess development of
well-differentiated airway epithelium. With increasing passage num-
ber, particularly for the dual SMAD inhibition culture, we noted pro-
gressive loss of ciliated cells, as measured by acetylated tubulin (Fig-
ure S1C). In order to measure CFTR ion transport function, ALI
cultures were subjected to Ussing chamber assays. Airway basal cells
expanded under Pneumacult Ex-Plus culture conditions exhibited
robust levels of CFTR function through at least p8, while basal cells
expanded in dual SMAD cultures exhibited lower levels of activity
(Figures S1D and S1E). Under either culture condition, further
passaging beyond p8 resulted in decreased levels of CFTR-dependent
transepithelial transport (Figure S1E). Based on the above, we chose
to perform our gene-editing manipulations on airway basal cells
maintained maximally until p6 to p8 (18–25 PDs) in the Pneuma-
cult Ex-Plus medium.
Sequence-Specific Correction of DF508 Mutation
Zinc-finger nucleases (ZFNs), targeted to recognize and cleave CFTR
DF508 sequences in exon 11 (ZFN11; Figure S2A), were delivered as





Figure 2. Sequence-Specific DF508 Correction with Restoration of Mature CFTR Protein Expression and Function
(A) Schematic of sequence-specific DF508 correction strategy. ZFNs were designed to site-specifically recognize and cleave CFTR DF508 sequences in exon 11 (ZFN11).
Two donors carrying correcting CFTR sequence are shown: a single stranded 200-mer oligo DNA donor (ssDNA) and 2 kb AAV-6 donor (containing 1,963 bp of wild-type
CFTR sequence spanning exon 11). Three anticipated outcomes are represented as unmodified, indels, and corrected. Primers f1 and r2, located outside the 1,963 bp donor
sequence, were used to amplify the targeted region in order to assess genome modification efficiency. (B) Efficiency of genome modification analyzed by NGS. Z, ZFN11
alone; Z+D, ZFN11 plus donor DNA (mean ± SD, n = 3 biological replicates; see also Table S1). (C) H&E staining and immunofluorescence detection of airway epithelium
markers in ALI culture. Major epithelial cell types were identified with markers: p63 or keratin 5 (CK5) for basal cells; mucin 5AC (MUC5AC) for secretory cells; acetylated
(legend continued on next page)
correction of the DF508 mutation, we evaluated two types of donor 
sequences encoding wild-type CFTR sequence. First, we co-delivered 
single-stranded (ss) 200-mer oligo DNAs together with the ZFN 
mRNAs via electroporation (Figure 2A). The ss oligo, centered on 
the DF508 mutation, included the wild-type restoring “CTT” bases 
(Figure S2A) spanned by approximately 100 bases of homology 
sequence on either side. In order to achieve maximal levels of correc-
tion while retaining cell viability, optimization was performed with 
respect to amount of ZFN mRNA (data not shown) and ssDNA 
donor oligo (e.g., Figures S2B and S2C). Next generation sequencing 
(NGS) was utilized to quantify the frequency of DF508 CFTR alleles 
exhibiting either no modification, indels, or correction (Figures 2A 
and 2B, Table S1). Delivery of ZFN mRNA alone resulted in 
44.6% ± 2.4% of CFTR alleles exhibiting indels. When ssDNA donor 
was co-delivered with ZFN mRNA, the frequency of DF508 correc-
tion was 10.6% ± 2.6% (all editing frequencies are expressed on a 
per CFTR allele basis) (Figure 2B; Table S1). We sought to modify 
our methodology in order to achieve significantly higher efficiencies 
of correction. To this end, we utilized a longer donor (2.0 kb, again 
centered on the correcting “CTT” bases), but in this case delivered via 
adeno-associated virus type 6 (AAV-6) (Figure 2A); AAV-6 was 
selected due to its favorable tropism for the lung.29,30 Optimization 
was again performed, in this case focused on the amount of ZFN 
and the AAV-6 dose (Figure S2D). Delivery of ZFN mRNA via elec-
troporation followed immediately thereafter by AAV-6 donor trans-
duction resulted in a correction efficiency of 31.0% ± 4.0% (Figure 2B; 
Table S1).
Sequence-Specific DF508 Correction Restores Mature CFTR 
Protein Expression and Function
In order to assess the functional consequences of DF508 correction, 
cells edited with the 2 kb AAV-6 donor were transferred onto porous 
supports and subjected to ALI culture conditions to generate well-
differentiated airway epithelium containing basal cells (p63, keratin 
5), secretory cells (mucin 5AC), ciliated cells (acetylated tubulin, 
FOXJ1), and ionocytes (FOXI1; Figures 2C and S3). Importantly, 
the manipulations required for editing did not alter the development 
of the pseudostratified epithelium. For example, cellular composition 
of the derived epithelium (i.e., % basal cells, % secretory cells, % cili-
ated cells, % ionocytes) was not affected by the manipulations 
(Figure S3).
As expected, ALI cultures derived from unmanipulated DF508/
DF508 airway basal cells only expressed the core glycosylatedtubulin (ACT) for ciliated cells. Representative 40 images in transverse section staining
correction restores expression of mature, fully glycosylated CFTR protein (band C). Ca
samples tested: DMSO-treated, VX-809/VX-770 pre-treated and Z+D-treated CF (DF50
chloride current stimulated by forskolin and inhibited by CFTR inhibitor 172 (CFTR inh-1
traces represented by (E). Values of Dlsc from samples listed in Table S2 are summarized
of gene-editing frequency. The blue symbols reflect results from individual DF508/DF508
or AAV-6 donor. CFTR activity (forskolin-induced) for each experiment is expressed a
experiment is from Table S1. Shown in open and filled blue circles are results of DF508
black filled circle is from DF508/DF508 cells. Linear regression for DF508 sequence-spCFTR protein (band B; Figure 2D), whereas non-CF ALI cultures
primarily exhibited the mature, fully-glycosylated, membrane-
bound form of CFTR (band C; Figure 2D). Importantly, the
AAV-6 edited DF508/DF508 cultures demonstrated the emergence
of band C, corresponding to the presence of corrected CFTR alleles
in the treated cells (Figures 2D and S4). Electrophysiological mea-
surement of CFTR channel function was performed via Ussing
chamber analysis. In Figure 2E, tracings for a representative exper-
iment are presented; results of several experiments are presented in
Table S2A and summarized in Figure 2F and Table S2B. As ex-
pected, non-treated DF508/DF508 cultures exhibit negligible forsko-
lin-activated CFTR current (Figure 2F). ALI cultures derived from
DF508/DF508 cells treated with ZFNs plus AAV-6 donor exhibited
CFTR-dependent current (20.2 ± 3.5 mA/cm2 (Figure 2F), robustly
blocked by the CFTR channel inhibitor (CFTRinh-172; Figures 2E
and 2F). This level of restored CFTR activity in edited cultures is
significant in two respects. First, this level of rescue in bulk-treated
DF508/DF508 cultures (with a mean correction efficiency of 31.0%;
Figure 2B) is 40.2% of that seen in the non-CF culture (50.2 ±
4.7 mA/cm2; Figure 2F). Second, this activity is 152% of that result-
ing from exposure of non-edited DF508/DF508 cells to the clinically
approved CFTR modulators VX-809 and VX-770 (13.3 ± 0.9 mA/
cm2; Figure 2F). This particular combination of modulators has
been shown to be of therapeutic benefit in DF508/DF508 CF pa-
tients31 and thus provides a metric against which the CFTR activity
in the edited DF508/DF508 cells can be compared. Thus, by both
measures (% of non-CF, % of VX-809/VX-770 treated DF508/
DF508), CFTR function resulting from this efficiency of DF508
correction is meaningful (see Discussion).
Similar analysis of ALI cultures derived from the 200-mer ssDNA
donor-corrected airway basal cells (mean correction frequency of
10.6%; Figure 2B; Table S1) also demonstrated restored expression
of mature CFTR protein (Figure S4), albeit at lower levels. For
ssDNA donor edited cells, the level of CFTR current was 13.2%
of the non-CF control (Tables S2A and S2B). However, rescue in
this case did not reach the level of the VX-809/VX-770 treated
DF508/DF508 control (21.3% of the non-CF control; Tables S2A
and S2B). For sequence-specific DF508 correction, we observed
an approximately linear correlation (R2 = 0.92) between the fre-
quency of correction and level of restored CFTR current (Fig-
ure 2G). Taken together, these data, comparing the ssDNA and
AAV-6 donors, support the importance of achieving significant
levels of editing.. Scale bar, 50 mm (panels). (D) Western blotting of CFTR. Sequence-specific DF508
lnexin, loading control. (E) Representative trace of short circuit current (Isc) from 4
8/DF508), and non-CF evaluated by Ussing chamber analysis. (F) Summary of CFTR
72). Difference of Isc (Dlsc) (mA/cm2) before and after treatments are calculated from
and shown (mean ± SD, n = 3 experiments). (G) Restored CFTR activity as function
cell experiments with sequence-specific correction of DF508 utilizing either ssDNA
s % of non-CF (e.g., see Table S2A). Frequency of genome modification for each
correction for DF508/DF508 cells with ssDNA and AAV-6 donors, respectively; the
ecific correction experiments resulted in an R2 = 0.92.
Efficient TI of SA-CFTR9-27-pA into CFTR Intron 8 of DF508/
DF508 Airway Basal Cells
We selected CFTR intron 8 to demonstrate proof of principle for the
homologous recombination-mediated TI approach. ZFNs targeting
CFTR intron 8 were designed and verified in K562 cells (data not
shown). In order to facilitate simultaneous quantification of both
the TI and indel frequencies in the same population of edited cells,
an intron 8 specific primer, followed by a random sequence and an
EcoRI site (to permit a rapid assessment of TI), was incorporated
into the donor immediately downstream of the SA-CFTR9-27-pA
cassette (Figure 3A); PCR amplification would yield a PCR product
of identical size as that from unmodified cells and NGS would permit
an accurate determination of TI and indel rates. We note the down-
stream primer was positioned outside of donor sequences to only
amplify from transgene sequences integrated at the targeted site (Fig-
ure 3A). Electroporation-mediated delivery of intron 8 ZFN mRNA
to DF508/DF508 airway basal cells was followed almost immediately
by AAV-6 transduction of SA-CFTR9-27-pA. Initial evidence for
sequence-specific TI of SA-CFTR9-27-pA into intron 8 came from up-
stream inside-outside PCR amplification (Figure S5A) and from
EcoRI digestion of downstream PCR amplicons (Figure S5B). These
results were quantified by NGS, with TI rates of 56.5% ± 7.4%
observed 4 days post editing (Figure 3B; Table S3A). Efficient intron
8 TI was confirmed by Southern blotting of genomic DNA isolated
from the edited DF508/DF508 cells (Figure 3C).
TI of SA-CFTR9-27-pA into CFTR Intron 8 of DF508/DF508 Airway
Basal Cells Restores Mature CFTR Protein Expression and
Function
Edited cells were plated in ALI cultures to develop well differentiated
epithelium as described previously. In the one experiment for which
we performed the analysis, we observed roughly comparable fre-
quencies of intron 8 TI in basal cells prior to plating in the ALI cul-
tures (50.1%) versus frequency of correction in mature, well differen-
tiated airway epithelium in ALI cultures (43.9%) (Table S3B). The TI
editing and minimal expansion required for early passage airway
basal cell cultures also did not adversely affect the ability to establish
well-differentiated airway epithelium comprising basal, secretory, and
ciliated cells (Figure 3D). Successful TI-mediated correction of bulk
cultures was confirmed by detection of CFTR transgene mRNA (Fig-
ure 3E) and by restoration of CFTR band C protein (Figure 3F). Us-
sing chamber assays from two independent experiments demon-
strated restoration of forskolin-activated CFTR currents in intron 8
TI cultures (Figure 3G; sample trace in Figure S5C). CFTR current
levels in edited cells from two independent experiments were 34.4%
to 42.7% of the level seen in non-CF cultures (Figure 3G). Further-
more, the mean level of restored CFTR channel activity was 157%
of the level seen for DF508/DF508 cultures exposed to VX-809/VX-
770 (Figure 3G). Thus, with our current TI efficiency, we are in a ther-
apeutically relevant range for amixed population of corrected and un-
corrected DF508/DF508 cells.
We also evaluated, in a limited number of experiments, the TI
strategy for intron 7 by delivery of intron 7 specific ZFNs followedshortly thereafter by AAV-6 delivery of a donor construct now
including CFTR exons 8 to 27 (SA-CFTR8-27-pA). Evidence for
intron 7 TI, first suggested via EcoRI digestion (Figure S6A), was
confirmed by NGS (Figure S6B). Successful targeting was
confirmed by expression of the transgenic mRNA (Figure S6C),
restored CFTR band C protein (Figure S6D), and restored CFTR
current (Figure S6E; sample trace in Figure S5C). This demon-
strates that potential effectiveness of the TI approach is not limited
to intron 8.
The level of TI-8 or TI-7 restored CFTR function in DF508/DF508
cells, as a function of editing efficiency, is shown in Figure 3H. These
results confirm significant CFTR functional restoration with the TI
approach. Given the limited number of experimental data points
for either the sequence-specific correction or TI approaches, it is pre-
mature to draw any firm conclusions, However, the tendency of the
TI data points to perhaps lie slightly below the sequence-specific
trendline suggests that further improvements may be possible (see
Discussion).
CFTR Intron 8 TI Preserves the Open Chromatin Structure of the
DF508/DF508 CFTR Locus
Our rationale for directly targeting integration of the partial CFTR
cDNA at the endogenous CFTR locus was to exploit the native
CFTR promoter and chromatin architecture, with the goal of
achieving physiologically relevant levels of restored CFTR protein
and function. The presence in ALI cultures of transgene-derived
CFTR mRNA (Figure 3E), protein (Figure 3F), and function (Fig-
ure 3G) from bulk TI-8 edited cells provides support for this target-
ing strategy. We further wished to confirm that neither the inte-
grated SA-CFTR9-27-pA transgene nor indels at the target site
significantly disrupted the sites of open chromatin normally present
in the native CFTR locus. To this end, we mapped, via Omni-ATAC-
seq, the sites of open chromatin in ALI cultures established from
TI-8 edited DF508/DF508 cells (Exp. 2; Table S3B; Figure 3G). At
this time point, 43.9% and 47.3% of the CFTR alleles exhibited TI
and indels, respectively (Table S3B). ALI cultures derived from un-
manipulated DF508/DF508 cells or non-CF cells were used as con-
trols. Significantly, Omni-ATAC-seq analysis of intron 8 targeted
ALI cultures revealed minimal impact on the positions of open chro-
matin within the native CFTR locus (Figure 4). Unaffected sites of
open chromatin included the CFTR topological domain boundaries
at80.1 kb and +48.9 kb, as well as the CFTR promoter and the pre-
viously identified 44 kb and 35 kb cis-regulatory elements
(CREs) shown to play a critical role in directing CFTR expression
in airway cells (Figure 4). Of note, other dominant peaks of open
chromatin observed across the locus in HBE-ALI cells (all of which
correspond to known CREs32) are also unaffected by the insertion.
Upon closer examination, we did observe a new site of accessible
chromatin near the start of the integrated SA-CFTR9-27-pA transgene
(Figure 4, lower panel). The significance of this particular finding is
unclear. In summary, we find that intron 8 TI of the transgene has






Figure 3. Efficient SA-CFTR9-27-pA TI into CFTR Intron 8 of DF508/DF508 Airway Basal Cells
(A) Schematic of site-specific targeted editing of CFTR intron 8. Unmodified and indel diagrams highlight CFTR genomic sequences between exons 8 and 9 (black
boxes; not to scale). TI-8 diagram shows intron 8 TI of human codon optimized CFTR9-27 cDNA preceded by a splice acceptor, followed by bovine growth hormone
(bGH) pA sequence, and flanked by 313 bp homology left (HL) and 351 bp homology right (HR) intron 8 sequences. Arrows indicate oligos amplifying unmodified, indel,
or TI-8 events and used to quantify frequency of each by NGS. (B) The percentage of genome modification (mean ± SD) determined by NGS (Table S3A) from five
independent TI-8 experiments (utilizing the AAV-6 donor at either 2  106 or 6  106 viral genomes [vg]/cell). There was no enhancement of TI efficiency as one
increased the amount of donor. Efficiency was measured 4 days after the delivery of ZFNs targeting intron 8 (ZFN8) followed immediately by AAV-6 CFTR9-27 cDNA
donor. Z, ZFN8 alone; Z+D, ZFN8 and AAV-6 donor. (C) Southern blot analysis of TI-8. The schematic shows the expected genomic organization of non-targeted (no
TI-8) and targeted (TI-8) alleles with the expected sizes resulting from EcoRI digestion. The non-targeted allele yields a 9.8 kb band while the TI-8 allele yields a 6.9 kb
band due to the new EcoRI site in the CFTR9-27 cDNA donor construct. (D) H&E staining and immunostaining of well-differentiated airway epithelium in ALI culture.
Representative images of cross sections from DF508/DF508 or TI-8 DF508/DF508. Immunostaining shows major epithelial cell types: basal cell (CK5 and P63),
secretory cells (MUC5AC), and ciliated cells (ACT). 40 images, scale bar, 50 mm. (E) Detection of transgene CFTR9-27 mRNA. Schematic of endogenous and
transgene CFTR mRNA is shown here. Primer T9 recognizes codon-optimized transgene exon 9 sequence only (blue) while Primer E9 recognizes endogenous exon 9.
A 250 bp E8-T9 RT-PCR amplicon, evidence of the chimeric endogenous-transgene CFTR mRNA, was present only in the TI-8 DF508/DF508 sample. (F) Restoration
of fully glycosylated CFTR protein via TI-8. Western blots of protein lysates harvested at 4 weeks of ALI culture. Band C, representing the mature, fully glycosylated
form of CFTR, is present in non-CF, absent in DF508/DF508 cells, and restored in TI-8 DF508/DF508. Calnexin, loading control. (G) CFTR functional assay in ALI
cultures at 4 weeks. TI-8 DF508/DF508 cells show the restoration of CFTR function measured as Dlsc (mA/cm2) ± SD and compared with DF508/DF508 treated with
VX-809/VX-770. (H) Restored CFTR activity as function of gene-editing frequency. The blue and black symbols and blue linear regression line are from individual
DF508/DF508 cell experiments with sequence-specific correction of DF508 (from Figure 2G). Shown in filled square and open square orange symbols are the results
of DF508/DF508 cell TI-8 and DF508/DF508 cell TI-7 experiments, respectively.
Figure 4. Targeted Integration of a Partial cDNA at CFTR Intron 8 Does Not Disrupt the Open Chromatin Profile of the DF508/DF508 CFTR Locus
Integrative Genomics Viewer (IGV) browser graphics of CFTR TAD regions showing Omni-ATAC profiles of non-CF, DF508/DF508, and TI-8 DF508/DF508 ALI cells. The
number of sequencing reads is shown in Table S7. Key cis-regulatory elements are marked above the ATAC profiles by arrows. DHS denotes all DNase I-hypersensitive sites
across the locus. Below is a magnified panel of the intron 8 region showing appearance of a peak of open chromatin at the TI-8 cDNA insertion site.Efficient TI Restores Mature CFTR Protein Expression and
Function in Airway Basal Cells Carrying CFTR Premature
Termination Codon Mutations
TI strategies as described here are highly relevant to CFTRmutations
resulting in little-or-no CFTR protein (for example, due to premature
termination codons [PTCs] or splicing defects); i.e., variants not
otherwise responsive to CFTR modulators. Evidence for sequence-
specific TI of SA-CFTR9-27-pA into intron 8 of DF508/R553X or
G542X/R785X airway basal cells was obtained from 50 inside-outside
PCR amplification (Figure S7A). Amplification using 30 PCR followed
by EcoRI digestion was consistent with efficient TI (Figure S7B). NGS
confirmed highly efficient TI in both the DF508/R553X (50.0% ±
6.0%) and G542X/R785X (61.8% ± 6.0%) airway basal cells (Tables
S3C and S3D; Figure 5A), and efficient intron 8 TI was confirmed
by Southern blot analysis (Figure 5B). Successful TI-mediated correc-
tion in the edited cultures was further established by restoration of
CFTR band C protein (Figure 5C). Ussing chamber assays demon-
strated restoration of forskolin-activated CFTR current in intron 8TI ALI cultures at levels 55.8% of non-CF cultures for DF508/
R553X and 33.8% of non-CF for G542X/R785X cultures (Figure 5D;
sample traces in Figures S7C and S7D). These results demonstrate
that targeted correction of PTC containing airway cells results in sig-
nificant restoration of CFTR channel activity, either when the PTC
occurs in combination with DF508 or with a second PTC.
DISCUSSION
In this study we have demonstrated highly efficient editing of the
mutant CFTR locus in primary CF airway basal cells. High efficiency
was achieved utilizing either a mutation-specific approach, demon-
strated for correction of DF508, or a mutation-agnostic approach,
requiring only that the CFTR mutation lies downstream of the tar-
geted integration. Our objective was to achieve an efficiency of gene
editing such that neither selection (e.g., via drug selection or sorting)
nor single-cell derived cloning would be required to obtain a pool of
cells corrected at a sufficiently high level to be directly transplantable.




Figure 5. Efficient TI-8 Correction in CF Airway Basal Cells Carrying CFTR PTC Mutations
(A) Frequency of genome modification determined by NGS in CF basal cells carrying DF508/R553X (mean ± SD, n = 3 experiments) or G542X/R785X (mean ± SD, n = 4
experiments) variants (from Tables S3C and S3D). Highly efficient TI-8 was confirmed in CF basal cells treated with ZFN8 and AAV-6CFTR9-27 cDNA donor (Z+D) 4 days after
genome editing. (B) Southern blot analysis of TI-8. A 6.9 kb fragment confirmed the expected TI-8 genomic organization in CF basal cells of either genotype. (C) Restoration of
fully glycosylated CFTR protein via TI-8. Western blot of protein lysates harvested at 4 weeks of ALI culture shows the presence of band C in TI-8 and the absence in non-
targeted cells. Calnexin, loading control. (D) CFTR functional assay in ALI cultures. Shown are short-circuit current measurements for bulk TI-8 DF508/R553X and TI-8
G542X/R785X cells. Restored CFTR currents are shown as Dlsc (mA/cm2) ± SD and are in excess of the VX-809/VX-770 treated cells. No VX-809/VX-770 response is
expected for G542X/R785X.primary airway basal stem cells; these levels of correction resulted in
restored CFTR function for the basal cell-derived airway epithelium.
Future studies will be required to determine how to prepare the CF
airways for receipt and integration of the edited airway basal cells
and how best to maximize the frequency of corrected cells in the re-
sulting engrafted airway tissue.33–35
For DF508-specific correction utilizing AAV-6 donor delivery, we
achieved correction to wild-type in approximately 30% of CFTR
alleles. These editing results are generally similar to those recently
reported for correction of DF508 in nasal and bronchial primary
epithelial cells mediated by CRISPR/Cas9 together with AAV-6.11
This 30% correction frequency corresponds to between 30% (if
both DF508 alleles per cell are restored) and 60% (if only one
DF508 allele is corrected per cell) of target cells demonstrating
correction. In principle, molecular characterization of individual
basal cells or single-cell-derived basal cell clones could provide a
more accurate quantitative assessment of correction (or indels)
on a per cell basis;36 this will be addressed in future studies. Impor-
tantly, neither the manipulations required for editing (i.e., electro-poration, AAV-6 transduction) nor the editing itself (i.e., correc-
tion, indels) altered the development or cellular composition of
the derived pseudostratified epithelium. Studies of various CFTR
mutations suggest that even very modest levels of CFTR gene
correction may provide therapeutic benefit. For example, as little
as 4.7% of the normal level of wild-type CFTR mRNA is sufficient
to result in a milder form of CF.37 In another study, 8% of wild-
type CFTR transcripts was suggested to be sufficient for normal
lung function.38 According to this measure, even our modest
10.6% ± 2.6% DF508 correction efficiency with the ssDNA oligo
donor, resulting in 13.2% ± 3.2% of wild-type current levels, might
offer partial therapeutic benefit. The restoration of CFTR activity
to levels 40.2% ± 4.7% of non-CF, resulting from AAV-6 delivery
of the 2 kb donor approximates a therapeutically beneficial range,
and exceeds the CFTR activity resulting from VX-809/VX-770
treatment (26.7% ± 3.6% of non-CF). Whereas the restoration of
CFTR activity in edited cultures is presumably due only to the frac-
tion of cells with correction, it is possible that modulators act more
generally. Administration of the VX-809/VX-770 drug combina-
tion to homozygous DF508 patients resulted in improvements in
FEV1, reduced rate of pulmonary exacerbations, reduced events
leading to hospitalization, and reduced use of intravenous
antibiotics.31
For sequence-specific DF508 correction, we observed an approxi-
mately linear correlation (R2 = 0.92) between the frequency of
DF508 correction and level of restored CFTR current (Figure 2G).
In mixing experiments of primary human airway cells, 10%:90%,
20%:80%, and 60%:40% mixtures of non-CF:DF508/DF508 cells
yielded CFTR chloride current at levels 35%, 70%, and 100%
that of non-CF cells;27 a linear relationship between CFTR current
and % non-CF cells was maintained up to approximately 20%
non-CF cell percentages.27 On first examination, our levels of
CFTR activity, as a function of gene-corrected cells, might appear
to be somewhat lower than would be predicted by the mixing exper-
iments. However, it is difficult to make direct comparisons of this
type since it is currently unknown precisely what percentage of
our cells were corrected at both CFTR alleles (corresponding to
the non-CF cells utilized in the mixing experiment described above)
versus at only a single CFTR allele per cell (corresponding to a car-
rier state). Although it might be assumed that carrier state cells
would have CFTR activity similar to that of non-CF cells, it has
been suggested that presence of the DF508 protein can adversely
affect the processing and chloride channel function of the wild-
type CFTR protein.39
While the mutation-specific editing approach achieved efficient
correction and restored CFTR activity, there are at least two poten-
tial drawbacks to this strategy. First is the potential requirement for
a new set of editing reagents (e.g., sequence specific nuclease and
donor) for each mutation or small region spanning several muta-
tions. Although this may be warranted for a common mutation
such as DF508, development of editing materials and performance
of clinical trials for each individual variant would be difficult.
Second, even in the presence of donor, a significant frequency of
CFTR alleles with nuclease-induced indels was observed; based
on other editing studies,36 as well as our own experience (data
not shown), introduction of indels at both alleles is expected to
occur with some frequency. For CFTR mutations occurring within
exon sequences (e.g., DF508), such residual indels would need to be
examined to ensure there are not unintended consequences, for
example the potential loss of response to current or future
modulators.
As an alternative strategy capable of treating airway basal cells car-
rying various CFTR mutations, we demonstrated efficient TI of
CFTR partial cDNA sequences into CFTR introns 7 and 8. We first
showed successful intron 8 TI in DF508/DF508 cells at efficiencies
56.5% ± 7.4% as measured 4 days after editing. Again, the manipula-
tions required for highly efficient editing (mean allele modification of
56.5% for TI and 33.0% for indels) did not adversely affect the ability
to establish well-differentiated airway epithelium. Intron 8 TI of
DF508/DF508 cells restored CFTR function to levels 34.4%–42.7%
of non-CF.By targeting integration of a CFTR partial cDNA to the endogenous
CFTR locus, our intent was to retain, to the greatest extent possible,
the regulated level and pattern of expression of the native gene.
Importantly, Omni-ATAC-seq analysis of the DF508/DF508 TI-8
ALI culture revealed no apparent alteration in the pattern of open
chromatin at previously identified regulatory sites within the CFTR
locus. This result is encouraging with respect to maintaining physio-
logically regulated transgene expression. We also demonstrated suc-
cessful TI and restoration of CFTR activity for TI-7. It is likely that
the overall reduced TI-7 efficiency (with respect to TI-8) is due to
the lower activity of the intron 7 ZFNs (with respect to the intron 8
ZFNs; Figures 3B and S6B)
Recently, there have been important advances in development of CF
modulators (e.g., the recently available triple drug combination)
potentially providing significant therapeutic benefit to the vast major-
ity of CF patients.40,41 Consequently, increased focus is now being
devoted to developing novel therapeutic approaches for the 7% of
CF patients who are unable to benefit from modulators, due to an
insufficient amount of CFTR protein (e.g., due to PTCs or splicing
mutations). We thus applied the TI methodology to restore CFTR
function in CF airway basal cells carrying PTCs. Again, we demon-
strated highly efficient TI-8 at frequencies 50.0% ± 6.0% and
61.8% ± 6.0% in DF508/R553X and G542X/R785X cells, respectively
(Figures 5A and 5B). After differentiation in ALI culture, restoration
of both CFTR protein (Figure 5C) and function (Figure 5D) were
observed.
In this project we evaluated TI for both introns 7 and 8. There are
several considerations relevant to determining which CFTR intron
is optimal for TI. One consideration would be to maximize the num-
ber of CF patients (or CFTR mutations) that could, in principle,
benefit from site-specific TI. We note that intron 8 TI, for example,
would provide correction for 89.1% of the CF-causing CFTR alleles
listed in the CFTR2 database: https://www.cftr2.org/ (March 2019
version). Notably, this includes DF508, several of the most common
PTCs such as G542X, R785X, and W1282X, and common splicing
mutations such as 3,849 + 10 kb C > T. A second consideration is
the size of the requisite CFTR partial cDNA and whether this can
be appropriately delivered with a chosen vector. Although intron 1
targeting would appear to be preferred (by providing correction for
all downstream mutations), limitations on packaging size for AAVs
(4.7 kb) potentially precludes incorporating SA-CFTR2-27-pA
together with homology arms of sufficient size for efficient homology
directed repair. A third aspect comprises the need to achieve integra-
tion without disrupting activity of critical CREs and the chromatin
architecture of the CFTR.
A further consideration in the selection of which intron to target in-
volves the relative strength(s) of the transgene splice acceptor versus
the native splice acceptor in the immediate downstream CFTR exon.
If the targeted intron were immediately upstream of a strong splice
acceptor sequence, then it is possible that a significant amount of
splicing could jump across the corrective partial CFTR cDNA. We
previously noted that the level of CFTR activity, as a function of edit-
ing frequency for either TI-7 or TI-8 (Figure 3H), was perhaps sugges-
tive of a reduction relative to that resulting from the same frequency 
of site-specific correction. To quantitatively assess what fraction of 
CFTR mRNA transcripts from targeted alleles were spliced from 
the endogenous exon 8 to the transgenic exon 9 (thus including trans-
genic corrective sequences) versus alternative splicing downstream to 
the endogenous exon 9 (including only endogenous mutant se-
quences), we examined several single-cell-derived clones exhibiting 
homozygous intron 8 TI (Figures S8A–S8C). Quantitative RT-PCR 
demonstrated that the majority (58.0%–89.9%; depending on the 
clone) of CFTR transcripts exhibited the desired splicing from the 
endogenous exon 8 into the corrective human codon optimized 
exon 9 sequences; however, 10.1%–42.0% of transcripts did, in fact, 
reflect splicing across the corrective exon sequences directly into 
endogenous mutant exon 9 sequences (Figure S8D). A failure to cap-
ture only corrective cDNA sequences in CFTR mRNA transcripts 
from successfully targeted alleles would potentially result in reduced 
levels of CFTR protein and activity as a function of editing frequency. 
This finding perhaps suggests room for improvement in the TI 
strategy (e.g., strengthening either the splice acceptor sequence or, 
alternatively the poly-adenylation sequence to maximize termination 
of transcription). In addition, it is possible that our use of non-native 
amino acid-encoding transgene sequences (i.e., human codon opti-
mized) may influence the efficiency of generating the appropriately 
folded CFTR protein necessary for functional activity.42
For any gene-editing approach, it is important to assess the nature 
and incidence of off-target effects that could potentially affect thera-
peutic safety. We experimentally identified via unbiased genome-
wide oligonucleotide capture, in K562 cells, potential off-target sites 
(Table S4) for the intron 8-specific ZFNs employed in the editing 
experiments reported in this study;43 we then quantitatively assessed 
the incidence of off-target indels in ZFN-treated primary DF508/
DF508 airway basal cells (Figure S9A). This validated the occurrence 
of indels at varying frequency at 10 of the previously identified 
off-target sites. Although all of these sites lie in intergenic or intronic 
sequences (Figure S9A), we chose to optimize the ZFN design, in 
order to reduce the frequency of such off-target indels, while still re-
taining recognition of the same intended target sequences.44 The 
improved intron 8 ZFNs maintained efficient on-target cleavage while 
exhibiting a significantly reduced incidence of off-target indels (Fig-
ure S9A). Importantly, the optimized ZFNs facilitated intron 8 TI 
of DF508/DF508 airway basal cells (Figures S9B and S9C) at levels 
similar to the original ZFNs.
Although we utilized airway epithelial cells from explanted lungs in 
these experiments, recently developed methodologies are capable of 
significantly expanding (ex vivo) the number of airway basal cells 
present in accessible primary tissues of CF patients, e.g., bronchial 
brushings (Figure S1A).28,45 These developments make possible the 
consideration of autologous, tissue-resident basal cells from CF pa-
tients, and their editing for therapeutic use. We have readily expanded 
basal cells obtained from airway brushings and do not anticipate anydifficulty in obtaining greater than the 6  107 cells estimated to be
required for engraftment in a human lung.33,46 There is compelling
clinical evidence that small airways are a critical site of early obstruc-
tion and disease.47 We expect that our studies using basal cells from
the large airways (bronchi) will be representative of basal cells from
bronchioles—an assertion that will require formal testing in the
future.
With the objective of generating CFTR-corrected patient-specific
airway basal stem cells, we have performed gene editing directly in
minimally expanded primary airway basal cells. It would, in principle,
be possible to first correct for CFTRmutations in CF patient induced
pluripotent stem cells (iPSCs) and then derive airway basal cells,
provided that robust differentiation protocols can be developed.
Whereas earlier work by our group and others utilized sequence-spe-
cific editing for correction of CF iPSCs,6,9,16 the TI of partial CFTR
cDNAs, as reported here, would represent a more generalizable
approach.5,7 Finally, we note that although the CFTR gene-editing
strategies pursued in the present studies were exclusively evaluated
on airway basal cells ex vivo, it is possible that these tools, appropri-
ately vectored, may eventually be applied for in vivo correction.
MATERIALS AND METHODS
Complete methods can be found in the Supplemental Information
online. All primary/secondary antibodies and oligos used in this
report are listed in Tables S5 and S6, respectively. Human subject re-
view was performed by University of Texas Health Science Center
institutional review committee.
Culture of Airway Basal Cells
Passage 1 CF and non-CF airway epithelial cells in this study were ob-
tained from the Tissue Procurement and Cell Culture core facility at
the University of North Carolina (Chapel Hill, NC, USA). Lungs were
obtained following informed consent under UNC Office of Human
Research Ethics/Institutional Review Board Study #03-1396 and cells
were isolated as previously described.48 Basal cells were cultured with
Pneumacult-Ex Plus medium (StemCell Technologies, Vancouver,
BC, Canada) on plates pre-coated with 804G cell-conditioned me-
dium (CM) and maintained at 37C in humidified air with 5%
CO2. At 50%–70% confluence, cells were dissociated by trypsinization
and either re-plated at a 1:10 ratio or directly utilized for gene editing.
Gene Editing
Gene editing of basal cells was performed by electroporation-medi-
ated delivery of ZFN mRNA (2–3 mg per reaction) followed immedi-
ately by AAV-6 donor transduction. Electroporations in this study
were performed with the BTX ECM 830 electroporation generator
(Harvard Apparatus, Holliston, MA, USA). The ZFNmRNA-electro-
porated cells were immediately transduced with AAV-6 donor at a
multiplicity of infection (MOI) of 2  6  106 viral genomes per
cell (vg/cell) overnight. Alternatively, for single-strand oligo DNA
donors (ssDNA), basal cells were co-electroporated with ZFN
mRNA and ssDNA and directly plated. All donor DNA sequences
are shown in the Supplemental Information (donor DNA sequences).
Assessment of Genome Modification
The efficiency of induction of on-target indels, sequence-specific
correction, and targeted integration was assessed quantitatively
through NGS deep sequencing on the Illumina platform. Examples
of sequencing data are uploaded in supplemental data files (Data S1
and S2). Additionally, targeted integration was confirmed by South-
ern blot analysis.In Vitro Differentiation of Basal Cells at Air Liquid Interface (ALI)
200,000 airway basal cells were seeded on a 6.5 mm Transwell with
0.4 mm pore polyester membrane inserts (Corning, Corning, NY,
USA) pre-coated with 804G-CM and subject to air liquid interface
culture with Pneumacult-ALI medium (StemCell Technologies) for
up to 4 weeks. Fully differentiated airway epithelia were confirmed
by hematoxylin and eosin (H&E) staining and immunofluorescence
analysis.Molecular and Functional Analysis
ALI-cultured cells were assayed forCFTRmRNA expression with RT-
PCR, CFTR protein expression via western blotting, and the func-
tional CFTR correction by Ussing chamber analysis as described pre-
viously with modification.16Omni Assay for Transposase Accessible Chromatin and Deep
Sequencing
Omni-ATAC-seq was performed on 50,000 cells as described previ-
ously with minor modifications.49 Omni-ATAC-seq libraries were
purified with Agencourt AMPure XP magnetic beads (Beckman
Coulter, Brea, CA, USA) with a sample to bead ratio of 1:1.2, and
eluted in Buffer EB (Hilden, Germany). Libraries were pooled and
sequenced on a HiSeq4000 machine (Illumina, San Diego, CA,
USA) with 100 bp paired end reads. Data were processed by the
ENCODE-DCC/atac-seq-pipeline. A custom genome was con-
structed using the Reform package (ver. August 2019) (https://
github.com/gencorefacility/reform) to insert the partial cDNA
sequence into the hg19 genome build.SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.
1016/j.ymthe.2020.04.021.AUTHOR CONTRIBUTION
Conceptualization: B.R.D., A.C., A.H.; Project Administration:
B.R.D., A.C., E.J.S., A.H.; Supervision: S.S.; Funding Acquisition:
B.R.D., A.C., E.J.S., A.H., S.H.R.; Methodology: S.S., A.M.C., N.M.;
Investigation: S.S., A.M.C., V.A., N.M., C.B., A.R., J.L.K., S.Y.,
M.M., K.K.; ZFN Design: L.Z.; Resources: S.H.R.; Writing – Original
Draft: B.R.D., A.C., S.S., A.M.C., A.H.; Writing – Review & Editing:
B.R.D., A.C., S.S., A.M.C., C.B., A.H., S.H.R., J.L.K., E.J.S.CONFLICTS OF INTEREST
A.C., M.M., K.K., and L.Z. are employees of Sangamo Therapeutics.ACKNOWLEDGMENTS
We gratefully acknowledge funding agencies enabling this study:
Cystic Fibrosis Foundation (CFF): SANGAM16X0 to A.C., DA-
VIS15XX0 and DAVIS17XX0 to B.R.D., RANDEL15XX0, RAN-
DEL17XX0, and BOUCHE15RO to S.H.R., and HARRIS15/17XX0,
HARRIS16G0, and HARRIS18P0 to A.H.; National Institutes of
Health (NIH): R01 HL139876 to E.J.S. and B.R.D., DK065988 to
S.H.R., and R01 HL094585 to AH; and UTHealth Pulmonary Center
of Excellence to B.R.D. We also acknowledge histological sample
preparation by Dr. Zhengmei Mao (UTHealth Microscopy Core Fa-
cility), Dr. Susan Reynolds for guidance and discussions, and Dr.
Hongmei Mou for guidance on the dual SMAD inhibition expansion
methodology and providing the 804G cell line.
REFERENCES
1. Hogan, B.L., Barkauskas, C.E., Chapman, H.A., Epstein, J.A., Jain, R., Hsia, C.C.,
Niklason, L., Calle, E., Le, A., Randell, S.H., et al. (2014). Repair and regeneration
of the respiratory system: complexity, plasticity, and mechanisms of lung stem cell
function. Cell Stem Cell 15, 123–138.
2. Rock, J.R., Onaitis, M.W., Rawlins, E.L., Lu, Y., Clark, C.P., Xue, Y., Randell, S.H., and
Hogan, B.L. (2009). Basal cells as stem cells of the mouse trachea and human airway
epithelium. Proc. Natl. Acad. Sci. USA 106, 12771–12775.
3. Rock, J.R., Randell, S.H., and Hogan, B.L. (2010). Airway basal stem cells: a perspec-
tive on their roles in epithelial homeostasis and remodeling. Dis. Model. Mech. 3,
545–556.
4. Hong, K.U., Reynolds, S.D., Watkins, S., Fuchs, E., and Stripp, B.R. (2004). Basal cells
are a multipotent progenitor capable of renewing the bronchial epithelium. Am. J.
Pathol. 164, 577–588.
5. Harrison, P.T., Hoppe, N., and Martin, U. (2018). Gene editing & stem cells. J. Cyst.
Fibros. 17, 10–16.
6. Firth, A.L., Menon, T., Parker, G.S., Qualls, S.J., Lewis, B.M., Ke, E., Dargitz, C.T.,
Wright, R., Khanna, A., Gage, F.H., and Verma, I.M. (2015). Functional gene correc-
tion for cystic fibrosis in lung epithelial cells generated from patient ipscs. Cell Rep.
12, 1385–1390.
7. Bednarski, C., Tomczak, K., Vom Hövel, B., Weber, W.M., and Cathomen, T. (2016).
Targeted integration of a super-exon into the cftr locus leads to functional correction
of a cystic fibrosis cell line model. PLoS ONE 11, e0161072.
8. Merkert, S., Bednarski, C., Göhring, G., Cathomen, T., and Martin, U. (2017).
Generation of a gene-corrected isogenic control iPSC line from cystic fibrosis pa-
tient-specific iPSCs homozygous for p.Phe508del mutation mediated by TALENs
and ssODN. Stem Cell Res. (Amst.) 23, 95–97.
9. Suzuki, S., Sargent, R.G., Illek, B., Fischer, H., Esmaeili-Shandiz, A., Yezzi, M.J., Lee,
A., Yang, Y., Kim, S., Renz, P., et al. (2016). Talens facilitate single-step seamless sdf
correction of f508del cftr in airway epithelial submucosal gland cell-derived cf-ipscs.
Mol. Ther. Nucleic Acids 5, e273.
10. Maule, G., Casini, A., Montagna, C., Ramalho, A.S., De Boeck, K., Debyser, Z., Carlon,
M.S., Petris, G., and Cereseto, A. (2019). Allele specific repair of splicing mutations in
cystic fibrosis through AsCas12a genome editing. Nat. Commun. 10, 3556.
11. Vaidyanathan, S., Salahudeen, A.A., Sellers, Z.M., Bravo, D.T., Choi, S.S., Batish, A.,
Le, W., Baik, R., de la, O.S., Kaushik, M.P., et al. (2020). High-efficiency, selection-free
gene repair in airway stem cells from cystic fibrosis patients rescues cftr function in
differentiated epithelia. Cell Stem Cell 26, 161–171.
12. Jennings, S., Ng, H.P., and Wang, G. (2019). Establishment of a DF508-CF promye-
locytic cell line for cystic fibrosis research and drug screening. J. Cyst. Fibros. 18,
44–53.
13. Ruan, J., Hirai, H., Yang, D., Ma, L., Hou, X., Jiang, H., Wei, H., Rajagopalan, C., Mou,
H., Wang, G., et al. (2019). Efficient gene editing at major cftr mutation loci. Mol.
Ther. Nucleic Acids 16, 73–81.
14. Ramalingam, S., London, V., Kandavelou, K., Cebotaru, L., Guggino, W., Civin, C.,
and Chandrasegaran, S. (2013). Generation and genetic engineering of human
induced pluripotent stem cells using designed zinc finger nucleases. Stem Cells Dev.
22, 595–610.
15. Valley, H.C., Bukis, K.M., Bell, A., Cheng, Y., Wong, E., Jordan, N.J., Allaire, N.E.,
Sivachenko, A., Liang, F., Bihler, H., et al. (2019). Isogenic cell models of cystic
fibrosis-causing variants in natively expressing pulmonary epithelial cells. J. Cyst.
Fibros. 18, 476–483.
16. Crane, A.M., Kramer, P., Bui, J.H., Chung, W.J., Li, X.S., Gonzalez-Garay, M.L.,
Hawkins, F., Liao, W., Mora, D., Choi, S., et al. (2015). Targeted correction and
restored function of the CFTR gene in cystic fibrosis induced pluripotent stem cells.
Stem Cell Reports 4, 569–577.
17. Sinn, P.L., Hwang, B.Y., Li, N., Ortiz, J.L.S., Shirazi, E., Parekh, K.R., Cooney, A.L.,
Schaffer, D.V., and McCray, P.B., Jr. (2017). Novel GP64 envelope variants for
improved delivery to human airway epithelial cells. Gene Ther. 24, 674–679.
18. Cooney, A.L., Thornell, I.M., Singh, B.K., Shah, V.S., Stoltz, D.A., McCray, P.B., Jr.,
Zabner, J., and Sinn, P.L. (2019). Novel aav-mediated gene delivery system corrects
cftr function in pigs. Am. J. Respir. Cell Mol. Biol. 61, 747–754.
19. Cmielewski, P., Donnelley, M., and Parsons, D.W. (2014). Long-term therapeutic and
reporter gene expression in lentiviral vector treated cystic fibrosis mice. J. Gene Med.
16, 291–299.
20. Yan, Z., McCray, P.B., Jr., and Engelhardt, J.F. (2019). Advances in gene therapy for
cystic fibrosis lung disease. Hum. Mol. Genet. 28 (R1), R88–R94.
21. Steines, B., Dickey, D.D., Bergen, J., Excoffon, K.J., Weinstein, J.R., Li, X., Yan, Z.,
Abou Alaiwa, M.H., Shah, V.S., Bouzek, D.C., et al. (2016). CFTR gene transfer
with AAV improves early cystic fibrosis pig phenotypes. JCI Insight 1, e88728.
22. Montoro, D.T., Haber, A.L., Biton, M., Vinarsky, V., Lin, B., Birket, S.E., Yuan, F.,
Chen, S., Leung, H.M., Villoria, J., et al. (2018). A revised airway epithelial hierarchy
includes CFTR-expressing ionocytes. Nature 560, 319–324.
23. Plasschaert, L.W., Zilionis, R., Choo-Wing, R., Savova, V., Knehr, J., Roma, G., Klein,
A.M., and Jaffe, A.B. (2018). A single-cell atlas of the airway epithelium reveals the
CFTR-rich pulmonary ionocyte. Nature 560, 377–381.
24. Okuda, K., Kobayashi, Y., Dang, H., Nakano, S., Barbosa Cardenas, S.M., On, V.K.,
Kato, T., Chen, G., Gilmore, R.C., Chua, M., et al. (2019). Regional regulation of
cftr and ionocyte expression in normal human airways. 2019 North American CF
Conference, Nashville TN, Pediatric Pulmonology, 54, Abstract 48.
25. Johnson, L.G., Olsen, J.C., Sarkadi, B., Moore, K.L., Swanstrom, R., and Boucher, R.C.
(1992). Efficiency of gene transfer for restoration of normal airway epithelial function
in cystic fibrosis. Nat. Genet. 2, 21–25.
26. Goldman, M.J., Yang, Y., andWilson, J.M. (1995). Gene therapy in a xenograft model
of cystic fibrosis lung corrects chloride transport more effectively than the sodium
defect. Nat. Genet. 9, 126–131.
27. Farmen, S.L., Karp, P.H., Ng, P., Palmer, D.J., Koehler, D.R., Hu, J., Beaudet, A.L.,
Zabner, J., and Welsh, M.J. (2005). Gene transfer of CFTR to airway epithelia: low
levels of expression are sufficient to correct Cl- transport and overexpression can
generate basolateral CFTR. Am. J. Physiol. Lung Cell. Mol. Physiol. 289, L1123–
L1130.
28. Mou, H., Vinarsky, V., Tata, P.R., Brazauskas, K., Choi, S.H., Crooke, A.K., Zhang, B.,
Solomon, G.M., Turner, B., Bihler, H., et al. (2016). Dual smad signaling inhibition
enables long-term expansion of diverse epithelial basal cells. Cell Stem Cell 19,
217–231.
29. Limberis, M.P., Vandenberghe, L.H., Zhang, L., Pickles, R.J., andWilson, J.M. (2009).
Transduction efficiencies of novel AAV vectors in mouse airway epithelium in vivo
and human ciliated airway epithelium in vitro. Mol. Ther. 17, 294–301.
30. Yan, Z., Lei-Butters, D.C., Keiser, N.W., and Engelhardt, J.F. (2013). Distinct trans-
duction difference between adeno-associated virus type 1 and type 6 vectors in hu-
man polarized airway epithelia. Gene Ther. 20, 328–337.
31. Wainwright, C.E., Elborn, J.S., Ramsey, B.W., Marigowda, G., Huang, X., Cipolli, M.,
Colombo, C., Davies, J.C., De Boeck, K., Flume, P.A., et al.; TRAFFIC Study Group;
TRANSPORT Study Group (2015). Lumacaftor-ivacaftor in patients with cystic
fibrosis homozygous for phe508del cftr. N. Engl. J. Med. 373, 220–231.
32. Swahn, H., and Harris, A. (2019). Cell-selective regulation of cftr gene expression:
Relevance to gene editing therapeutics. Genes (Basel) 10, E235.33. Ghosh, M., Ahmad, S., White, C.W., and Reynolds, S.D. (2017). Transplantation of
airway epithelial stem/progenitor cells: A future for cell-based therapy. Am. J.
Respir. Cell Mol. Biol. 56, 1–10.
34. Milman Krentsis, I., Rosen, C., Shezen, E., Aronovich, A., Nathanson, B., Bachar-
Lustig, E., Berkman, N., Assayag, M., Shakhar, G., Feferman, T., et al. (2018). Lung
injury repair by transplantation of adult lung cells following preconditioning of recip-
ient mice. Stem Cells Transl. Med. 7, 68–77.
35. Farrow, N., Cmielewski, P., Donnelley, M., Rout-Pitt, N., Moodley, Y., Bertoncello, I.,
and Parsons, D. (2018). Epithelial disruption: a new paradigm enabling human
airway stem cell transplantation. Stem Cell Res. Ther. 9, 153.
36. Park, S.H., Lee, C.M., Dever, D.P., Davis, T.H., Camarena, J., Srifa, W., Zhang, Y.,
Paikari, A., Chang, A.K., Porteus, M.H., et al. (2019). Highly efficient editing of the
b-globin gene in patient-derived hematopoietic stem and progenitor cells to treat
sickle cell disease. Nucleic Acids Res. 47, 7955–7972.
37. Ramalho, A.S., Beck, S., Meyer, M., Penque, D., Cutting, G.R., and Amaral, M.D.
(2002). Five percent of normal cystic fibrosis transmembrane conductance regulator
mRNA ameliorates the severity of pulmonary disease in cystic fibrosis. Am. J. Respir.
Cell Mol. Biol. 27, 619–627.
38. Chu, C.S., Trapnell, B.C., Curristin, S.M., Cutting, G.R., and Crystal, R.G. (1992).
Extensive posttranscriptional deletion of the coding sequences for part of nucleo-
tide-binding fold 1 in respiratory epithelial mRNA transcripts of the cystic fibrosis
transmembrane conductance regulator gene is not associated with the clinical man-
ifestations of cystic fibrosis. J. Clin. Invest. 90, 785–790.
39. Tucker, T.A., Fortenberry, J.A., Zsembery, A., Schwiebert, L.M., and Schwiebert, E.M.
(2012). TheDF508-CFTRmutation inhibits wild-type CFTR processing and function
when co-expressed in human airway epithelia and in mouse nasal mucosa. BMC
Physiol. 12, 12.
40. Keating, D., Marigowda, G., Burr, L., Daines, C., Mall, M.A., McKone, E.F., Ramsey,
B.W., Rowe, S.M., Sass, L.A., Tullis, E., et al.; VX16-445-001 Study Group (2018). Vx-
445-tezacaftor-ivacaftor in patients with cystic fibrosis and one or two phe508del al-
leles. N. Engl. J. Med. 379, 1612–1620.
41. Middleton, P.G., Mall, M.A., Drevínek, P., Lands, L.C., McKone, E.F., Polineni, D.,
Ramsey, B.W., Taylor-Cousar, J.L., Tullis, E., Vermeulen, F., et al.; VX17-445-102
Study Group (2019). Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single
phe508del allele. N. Engl. J. Med. 381, 1809–1819.
42. Kim, S.J., Yoon, J.S., Shishido, H., Yang, Z., Rooney, L.A., Barral, J.M., and Skach,
W.R. (2015). Protein folding. Translational tuning optimizes nascent protein folding
in cells. Science 348, 444–448.
43. Tsai, S.Q., Zheng, Z., Nguyen, N.T., Liebers, M., Topkar, V.V., Thapar, V., Wyvekens,
N., Khayter, C., Iafrate, A.J., Le, L.P., et al. (2015). GUIDE-seq enables genome-wide
profiling of off-target cleavage by CRISPR-Cas nucleases. Nat. Biotechnol. 33,
187–197.
44. Miller, J.C., Patil, D.P., Xia, D.F., Paine, C.B., Fauser, F., Richards, H.W., Shivak, D.A.,
Bendaña, Y.R., Hinkley, S.J., Scarlott, N.A., et al. (2019). Enhancing gene editing spec-
ificity by attenuating DNA cleavage kinetics. Nat. Biotechnol. 37, 945–952.
45. Butler, C.R., Hynds, R.E., Gowers, K.H., Lee, Ddo.H., Brown, J.M., Crowley, C.,
Teixeira, V.H., Smith, C.M., Urbani, L., Hamilton, N.J., et al. (2016). Rapid expansion
of human epithelial stem cells suitable for airway tissue engineering. Am. J. Respir.
Crit. Care Med. 194, 156–168.
46. Hayes, D., Jr., Kopp, B.T., Hill, C.L., Lallier, S.W., Schwartz, C.M., Tadesse, M.,
Alsudayri, A., and Reynolds, S.D. (2019). Cell therapy for cystic fibrosis lung disease:
Regenerative basal cell amplification. Stem Cells Transl. Med. 8, 225–235.
47. Rosenow, T., Ramsey, K., Turkovic, L., Murray, C.P., Mok, L.C., Hall, G.L., Stick,
S.M., and Arest, C.F.; AREST CF (2017). Air trapping in early cystic fibrosis lung dis-
ease-Does CT tell the full story? Pediatr. Pulmonol. 52, 1150–1156.
48. Fulcher, M.L., and Randell, S.H. (2013). Human nasal and tracheo-bronchial respira-
tory epithelial cell culture. Methods Mol. Biol. 945, 109–121.
49. Corces, M.R., Trevino, A.E., Hamilton, E.G., Greenside, P.G., Sinnott-Armstrong,
N.A., Vesuna, S., Satpathy, A.T., Rubin, A.J., Montine, K.S., Wu, B., et al. (2017).
An improved ATAC-seq protocol reduces background and enables interrogation
of frozen tissues. Nat. Methods 14, 959–962.
